Literature DB >> 8287395

Acute myocardial infarction in dogs with experimental diabetes.

R Forrat1, L Sebbag, N Wiernsperger, J Guidollet, S Renaud, M de Lorgeril.   

Abstract

OBJECTIVE: The aim was to examine whether diabetes interferes with the development of myocardial injury in a canine ischaemia-reperfusion model.
METHODS: Non-insulin-requiring diabetes was induced in dogs by the streptozotocin-alloxan method. After 75 d, the dogs were anaesthetised and myocardial infarction was provoked by occluding the left anterior descending coronary artery for 2 h followed by 6 h reperfusion.
RESULTS: Diabetic dogs had higher blood glucose [9.4(SEM 1) mmol.litre-1], fructosamine [417(57) mumol.litre-1], and glycated haemoglobin [3.3(0.7)%], than control dogs [5.5(0.6), p = 0.04, 243(15), p = 0.01, and 0.7(0.2), p = 0.003, respectively], and they also had higher serum lipids (p = 0.001) and platelet aggregation (p = 0.03). Area at risk was similar in diabetic and control dogs but in contrast to controls (r = 0.78, p = 0.007), area at risk and infarct size were not correlated in diabetics (r = 0.08). In both groups, collateral flow was the major determinant of infarct size: r = -0.73 in controls (p = 0.02) and -0.97 in diabetics (p = 0.001). In spite of higher subendocardial collateral flow in diabetics [representing 21.6(6)% of the flow in the corresponding non-ischaemic zone] than in controls [11.2(6)%], infarct size was similar in both groups. However, the mean observed infarct size in the diabetic group [7.5(2.8)% of the left ventricle] was significantly (p < 0.03) larger than the mean predicted infarct size [5.2(2)%]. Multivariate analysis confirmed that diabetes, as well as collateral flow, is an independent (p = 0.03) predictor of infarct size.
CONCLUSIONS: For a given collateral flow, diabetic dogs develop larger infarcts than controls. Further studies are required to investigate the biochemical mechanism(s) underlying this deleterious effect. However, this may partly explain the poor prognosis of myocardial infarction in diabetic persons.

Entities:  

Mesh:

Year:  1993        PMID: 8287395     DOI: 10.1093/cvr/27.11.1908

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  20 in total

1.  AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings.

Authors:  Yanqing Zhang; Jianli Zhao; Rui Li; Wayne Bond Lau; Yue-Xing Yuan; Bin Liang; Rong Li; Er-He Gao; Walter J Koch; Xin-Liang Ma; Ya-Jing Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-02       Impact factor: 4.310

2.  Hyperoxia-induced cardiotoxicity and ventricular remodeling in type-II diabetes mice.

Authors:  Jennifer Leigh Rodgers; Eva Samal; Subhra Mohapatra; Siva Kumar Panguluri
Journal:  Heart Vessels       Date:  2017-12-05       Impact factor: 2.037

Review 3.  Metabolic abnormalities in the diabetic heart.

Authors:  Gary D Lopaschuk
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

4.  Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury.

Authors:  Yajing Wang; Wayne Bond Lau; Erhe Gao; Ling Tao; Yuexing Yuan; Rong Li; Xiaoliang Wang; Walter J Koch; Xin-Liang Ma
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-22       Impact factor: 4.310

5.  Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart.

Authors:  T Ravingerová; A Adameová; J Matejíková; T Kelly; M Nemčeková; J Kucharská; O Pecháňová; A Lazou
Journal:  Exp Clin Cardiol       Date:  2010

6.  Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.

Authors:  S B Kristiansen; B Løfgren; N B Støttrup; D Khatir; J E Nielsen-Kudsk; T T Nielsen; H E Bøtker; A Flyvbjerg
Journal:  Diabetologia       Date:  2004-10-07       Impact factor: 10.122

7.  Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo.

Authors:  Dirk Ebel; Jost Müllenheim; Jan Frässdorf; Andre Heinen; Ragnar Huhn; Thomas Bohlen; Jan Ferrari; Hendrik Südkamp; Benedikt Preckel; Wolfgang Schlack; Volker Thämer
Journal:  Pflugers Arch       Date:  2003-03-26       Impact factor: 3.657

8.  AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin.

Authors:  Yajing Wang; Erhe Gao; Ling Tao; Wayne Bond Lau; Yuexin Yuan; Barry J Goldstein; Bernard L Lopez; Theodore A Christopher; Rong Tian; Walter Koch; Xin-Liang Ma
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

9.  Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Authors:  Ling Tao; Yajing Wang; Erhe Gao; Hangxiang Zhang; Yuexing Yuan; Wayne B Lau; Lawrence Chan; Walter J Koch; Xin L Ma
Journal:  Circ Res       Date:  2009-11-25       Impact factor: 17.367

10.  Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats.

Authors:  Jiung-Pang Huang; Shiang-Suo Huang; Jen-Ying Deng; Li-Man Hung
Journal:  J Biomed Sci       Date:  2009-08-25       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.